Mosquitos are the deadliest of all creatures, so scientists are trying a new idea: Creating even more deadly mosquitos to fight back. » Read More
By: Gina Francolla
The iShares Nasdaq Biotechnology Index ETF is on pace for its fourth-straight day of gains. » Read More
By: Dan Mangan
As Shkreli's trial ends its fourth week, fraying nerves have led to sniping between lawyers. » Read More
By: Jay Hancock, Elizabeth Lucas & Sydney Lupkin
Wall Street was spending a half-billion dollars on Mallinckrodt drug with limited evidence of effectiveness, N.Y. Times reports. » Read More
Earlier the iShares NASDAQ Biotechnology ETF (IBB) gained about 1 percent, but reversed its course after Clinton's tweet.
Bill George, Harvard Business School professor & fmr. Medtronic chairman and CEO, shares his take on Mylan and the EpiPen pricing outrage.
CNBC's Meg Tirrell reports the latest on Mylan's controversial EpiPen price hike.
AstraZeneca has agreed to sell its small molecule antibiotics business to Pfizer in a deal that could be valued at more than $1.5 billion.
U.K. pharma giant agrees to sell its small molecule antibiotics business to Pfizer of the U.S.
Clovis Oncology shares shot up more than 26 percent Tuesday after the FDA accepted the company's new drug application.
Mylan raised the prices of 24 drug products more than 20 percent. One went up by 542 percent. Another by 444 percent.
Shares of Clovis surge on positive FDA news, CNBC's Melissa Lee reports.
How is the EpiPen outrage impacting families, parents and children who need these products as protection against fatal allergy attacks? CNBC's Kate Kelly and Sue Herera discuss how its affecting their own children.
Tim Chiang, BTIG managing director, shares his take on Mylan, admid the EpiPen price outrage.
As Mylan's EpiPen prices rose by more than 400 percent, pay for its top executive jumped by more than 600 percent, NBC News reports.
The price of a pack of life-saving EpiPens shot up to $400. This is out of control, says Jake Novak. But, there IS a solution.
Mylan has increased the price of the anti-allergy device EpiPen more than five-fold in recent years.
Alex Tarrant, assistant editor at Dealreporter Europe, Mergermarket Group, shares his views on the deal between Pfizer and Medivation.
Pharmaceutical firms rely on acquisitions to plug the gap on innovations they do not currently possess, says Albert Fried and Company's Sachin Shah.
Pfizer investors should be concerned about the high premium, while Medivation investors should celebrate, says RBC Capital Markets' Simos Simeonidis.
CNBC's Meg Tirrell reports on the action in the IBB biotech ETF after Pfizer announced it was buying Medivation and what some other big M&A deals could be coming down the line. The "Fast Money" traders weigh in.
CNBC's Meg Tirrell reports on shares of EpiPen maker Mylan dropping following increasing questions over its pricing. The "Fast Money" traders weigh in.
A growing chorus is calling on the Mylan pharmaceutical company to justify its price hikes on EpiPens, NBC News reports.
Iowa Senator Chuck Grassley sends a letter to Mylan CEO Heather Bresch about EpiPen pricing. CNBC's Meg Tirrell reports.
Get the best of CNBC in your inbox